UNSPSC 51402304: Revospirone

This classification denotes an anxiolytic with the molecular formula C18H21N5O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6X8764TW2J, chemically known as 1,2-benzisothiazol-3(2h)-one, 2-(3-(4-(2-pyrimidinyl)-1-piperazinyl)propyl)-, 1,1-dioxide but generally known as revospirone, which bears US NIH Compound Identifier 72024. European Medicines Agency schedules Revospirone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10296MIG. The term REVOSPIRONE is an International Non-Proprietary Name.

UNSPSC 51402304 Revospirone, a Commodity code, represents pharmaceutical products that state and local governments procure through health and human services channels, though recent solicitations under this code tag show limited direct activity for the compound itself. Instead, the solicitations capture broader pharmaceutical procurement patterns: Seminole County, Florida sought naloxone and drug deactivation systems through competitive bidding; the Texas Health and Human Services Commission issued a Request for Information on direct-to-manufacturer prescription programs; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued an RFP for generic multi-source pharmaceuticals and over-the-counter products. The issuing bodies span county health departments, state HHS agencies, and multi-state cooperative purchasing vehicles, reflecting the range of jurisdictions that source medications and pharmaceutical supplies for public health and community support programs. Work solicited includes product supply, quarterly or regular distribution logistics, manufacturer certification compliance (cGMP and Drug Supply Chain Security Act), wholesaler relationship management, and pricing flexibility across multiple net formats.

Recent activity concentrates in Florida, Texas, and the Upper Midwest through MMCAP's multi-state vehicle serving state and local facilities in Minnesota and Oregon. The Seminole County IFB (Solicitation IFB60459723LAS, response due July 26, 2023) sought 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries; the Texas HHS RFI (HHS0017013, response deadline April 3, 2026) gathered market intelligence on direct-to-manufacturer prescription contracting models outside traditional pharmacy benefit manager arrangements; and the MMCAP RFP (S1070000015802, responses due March 26, 2026) established multi-contract vehicles for generic pharmaceuticals and OTC products through three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, and Morris & Dickson), with contract effectiveness July 1, 2026. The code itself shows no dominant repeat buyer or geographic concentration — activity reflects dispersed state and local health procurement across multiple jurisdictions and procurement vehicles.